BetterLife Pharma Inc. focuses on developing compounds for treating mental disorders in Canada. The company faces significant concerns, including a very low current ratio of 0.04, indicating liquidity issues, and a negative return on assets of -215.6%, suggesting inefficiency in asset utilization. The stock price is currently at $0.24, reflecting a decline of 2.04%, which may raise concerns about investor confidence. Overall, while the company operates in a critical healthcare sector, its financial health raises red flags that potential investors should consider.
Loading financial metrics...
Company has $22K in cash but burned $87K last quarter. At this burn rate, only 0.3 quarters of runway remain without additional financing.
Company posted a loss of $-840K over the last year, representing Infinity% of revenue.
Debt of $1.0M is 46.3x the company's cash position of $22K.
Operating cash flow has been negative for 3 consecutive quarters, burning $348K over the last year.
No significant opportunities identified
Based on current financial metrics
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2025-Q3 (July 31, 2025)